Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
OwnerDonald Leung, Janine Bilsborough +1inventors
InventorsDonald Leung, Janine Bilsborough, Jane Gross
Life of this patent
Estimating the term…
Abstract
The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
Claims17
A method of treating atopic dermatits skin comprising administering an antagonist molecule to a mammal with the atopic dermatitis skin wherein the skin is characterized by cutaneous lymphocyte antigen positive T cells and the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:2 or SEQ ID NO:
- 4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the diseased skin.
A method for treating pruritis from atopic dermatitis comprising administering an antagonist molecule to a mammal with the pruritis wherein the pruritis is characterized by cutaneous lymphocyte antigen positive T cells and wherein the antagonist molecule specifically binds to the polypeptide having the amino acid sequence as shown in SEQ ID NO:2 or in SEQ ID NO:
- 4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the pruritis.
A method for predicting therapeutic response to an IL-31 antagonist in an individual with atopic dermatitis in need of IL-31 antagonist therapy comprising obtaining a biological sample from the patient, isolating circulating cutaneous lymphocyte positive T cells from the biological sample, and detecting IL-31 production from the isolated cutaneous lymphocyte positive T cells.
Dependencies are inferred from the claim text.